# Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study

> **NCT07163611** · PHASE2,PHASE3 · RECRUITING · sponsor: **Radboud University Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- Membranous Nephropathy - PLA2R Induced

## Interventions

- **DRUG:** Obinutuzumab administration

## Key facts

- **NCT ID:** NCT07163611
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07163611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07163611, "Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07163611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*